zoledronic acid and Genetic Predisposition
zoledronic acid has been researched along with Genetic Predisposition in 4 studies
Research
Studies (4)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Cserepes, M; Dobos, J; Hegedűs, B; Horváth, O; Izsák, V; Kenessey, I; Kói, K; Molnár, D; Tímár, J; Tóvári, J | 1 |
Brandi, ML; Cavalli, L; Cavalli, T; Falchetti, A; Marini, F; Masi, L; Tonelli, P | 1 |
Arbitrio, M; Baudi, F; Calimeri, T; Cannataro, M; Cucinotto, I; Di Martino, MT; Guzzi, PH; Leone, E; Piro, E; Prantera, T; Rossi, M; Tagliaferri, P; Tassone, P; Veltri, P | 1 |
Bandeira, F; Colares, V; Griz, L | 1 |
Reviews
1 review(s) available for zoledronic acid and Genetic Predisposition
Article | Year |
---|---|
[Treatment of Paget's disease of bone: importance of the zoledronic acid].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Pamidronate; Remission Induction; Treatment Outcome; Zoledronic Acid | 2006 |
Other Studies
3 other study(ies) available for zoledronic acid and Genetic Predisposition
Article | Year |
---|---|
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Diphosphonates; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Humans; Imidazoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, SCID; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Phenotype; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Gene Frequency; Genetic Predisposition to Disease; Geranyltranstransferase; Humans; Imidazoles; Italy; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies; White People; Zoledronic Acid | 2011 |
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Gene Frequency; Genetic Predisposition to Disease; Humans; Imidazoles; Jaw Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Polymorphism, Single Nucleotide; PPAR gamma; Zoledronic Acid | 2011 |